MX2023010614A - Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida. - Google Patents

Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.

Info

Publication number
MX2023010614A
MX2023010614A MX2023010614A MX2023010614A MX2023010614A MX 2023010614 A MX2023010614 A MX 2023010614A MX 2023010614 A MX2023010614 A MX 2023010614A MX 2023010614 A MX2023010614 A MX 2023010614A MX 2023010614 A MX2023010614 A MX 2023010614A
Authority
MX
Mexico
Prior art keywords
sup
crystalline
crystalline modification
dibenzenaheptaphane
triazola
Prior art date
Application number
MX2023010614A
Other languages
English (en)
Inventor
Susanne Röhrig
Britta Olenik
Tia Jacobs
Guillaume Levilain
Michal Sowa
Franco Rubino
Krischan Ziem
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2023010614A publication Critical patent/MX2023010614A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a formas cristalinas de (4S)-24-cloro-4-etil-73-fluoro-35-metoxi-32,5-dioxo-14-(trifluoro metil)-32H-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida que son la modificación cristalina I y la modificación cristalina II, a procesos para su preparación, a composiciones farmacéuticas que las comprenden y a su uso en el control de trastornos.
MX2023010614A 2021-03-09 2022-03-04 Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida. MX2023010614A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21161489 2021-03-09
PCT/EP2022/055521 WO2022189279A1 (en) 2021-03-09 2022-03-04 Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide

Publications (1)

Publication Number Publication Date
MX2023010614A true MX2023010614A (es) 2023-09-19

Family

ID=74867465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010614A MX2023010614A (es) 2021-03-09 2022-03-04 Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.

Country Status (15)

Country Link
US (1) US20240174633A1 (es)
EP (1) EP4304714A1 (es)
JP (1) JP2024508971A (es)
KR (1) KR20230155505A (es)
CN (1) CN117015535A (es)
AU (1) AU2022235150A1 (es)
BR (1) BR112023016298A2 (es)
CA (1) CA3212645A1 (es)
CL (1) CL2023002676A1 (es)
CO (1) CO2023011801A2 (es)
DO (1) DOP2023000170A (es)
IL (1) IL305231A (es)
MX (1) MX2023010614A (es)
TW (1) TW202302561A (es)
WO (1) WO2022189279A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283464B1 (en) 2015-04-16 2019-10-23 Merck Sharp & Dohme Corp. Factor xia inhibitors
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
PT3765452T (pt) 2018-03-15 2022-06-23 Bayer Pharma AG Processo preparativo de dois derivados de 4-{[(2s)-2-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida
CA3123324A1 (en) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
JOP20210161A1 (ar) 2018-12-21 2023-01-30 Bayer Ag مشتقات أكسوبيريدين تحمل بدائل

Also Published As

Publication number Publication date
TW202302561A (zh) 2023-01-16
BR112023016298A2 (pt) 2023-10-03
CL2023002676A1 (es) 2024-02-09
KR20230155505A (ko) 2023-11-10
IL305231A (en) 2023-10-01
EP4304714A1 (en) 2024-01-17
CA3212645A1 (en) 2022-09-15
CN117015535A (zh) 2023-11-07
DOP2023000170A (es) 2023-09-29
WO2022189279A1 (en) 2022-09-15
US20240174633A1 (en) 2024-05-30
AU2022235150A1 (en) 2023-08-31
CO2023011801A2 (es) 2023-09-18
JP2024508971A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
US11633414B2 (en) Nicotinoyl riboside compositions and methods of use
EP1725536B8 (en) Imidazoline derivatives having cb1-antagonistic activity
MX2023010614A (es) Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
MXPA04004465A (es) Banzamida, heteroarilamida y amidas inversas.
TW200514781A (en) Novel compounds
HU203543B (en) Process for producing cyclohexane derivatives and pharmaceutical compositions containing them
JPH11511481A (ja) 免疫抑制活性を有するトリテルペン誘導体
KR101890058B1 (ko) 신규한 마리올라이드 유도체 및 이를 함유하는 만성 염증성 질환의 예방 또는 치료용 조성물
DE69623760T2 (de) Kaliumionen-kanal-blocker
AU2292900A (en) Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them
ZA909774B (en) Substituted cyclohexenes as central nervous system agents
TR200002795T2 (tr) FP Agonistleri olarak yararlı olan C11 oksimil ve hidroksilamino prostaglandinleri.
AU2014335860B2 (en) Chromene derivatives as inhibitors of TCR-Nck interaction
WO2011161151A1 (de) Verwendung von dibenzofuranonderivaten zur inhibierung von kinasen
Şimşek et al. Studies on calcium antagonist activities of 2-ethyl-3-carbmethoxy-4-aryl-5-oxo-6, 6-dimethyl-1, 4, 5, 6, 7, 8-hexahydroquinoline derivatives
CA2534824A1 (en) 1h-imidazole derivatives as cannabinoid receptor modulators
US5162569A (en) Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
JP2021506798A (ja) 置換テトラヒドロピランジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
DE4217963A1 (de) Verwendung von Indolocarbazolen zur Behandlung von AIDS
RU2789377C2 (ru) Новые спиробициклические аналоги
WO2024069007A2 (en) Immunosuppressive compounds
HU207065B (en) Process for producing 1-ethylphenoxathiin-10,10-dioxide and pharmaceutical compositions comprising such compounds as active ingredient
CN115124499A (zh) 一种靶向杀伤老化细胞的化合物及其应用
EP1451308A2 (en) Therapeutic use of aziridino compounds
CA2270026A1 (en) Substituted bicyclic derivatives for treating central nervous system disorders